Gene therapy
•Download as DOCX, PDF•
0 likes•65 views
Diabetic retinopathy is a leading cause of vision loss, caused by neovascularization and vascular leakage due to prolonged high blood sugar levels. Current treatments using anti-VEGF drugs require frequent reinjections that cause side effects. Gene therapy offers prolonged expression to reduce the need for multiple injections. The document proposes delivering genes for angiopoietins 1, 2, and 4 via an AAV vector in a rat model of diabetic retinopathy, as angiopoietins may help prevent neovascularization and leakage in patients who do not fully respond to anti-VEGF treatment. This could minimize vision loss and blindness for those with advanced or resistant disease.
Report
Share
Report
Share
Recommended
Diabetic retinopathy group 7 period 2 #
Diabetic retinopathy is damage to the retina caused by long-term diabetes. It affects people with type 1 and type 2 diabetes, especially Hispanics and African Americans over 30 years old. Symptoms include blurred vision and potential complications like cataracts or retinal detachment. The disease infects blood vessels in the eyes, blocking them and causing bleeding and fluid buildup in the retina. Treatment focuses on controlling blood sugar and blood pressure as well as laser treatments and surgery to repair damage.
Presentation p2 good_one[1]
Diabetic retinopathy is a complication of diabetes that affects the eyes. It damages the blood vessels in the retina and can lead to vision loss over time if not treated. People with type 1 or type 2 diabetes, especially those who have had the disease for a long time, are at higher risk. Symptoms may include blurred vision, spots in vision, and eye pain. Treatment focuses on controlling blood sugar and blood pressure as well as laser treatments or surgery in severe cases to prevent further vision loss.
Advances in retina and nutrition in amd
This document discusses advances in treating age-related macular degeneration (AMD) through retina research and nutrition. It defines the two types of AMD - dry and wet - and explains their symptoms and stages. Treatment for dry AMD focuses on antioxidant and zinc supplementation based on the AREDS studies. Wet AMD is treated using anti-VEGF injections into the eye. The role of diet, genetics, and modifiable risk factors like smoking are also discussed. Case studies demonstrate treatment outcomes for patients receiving injections for wet AMD.
DIABETIC RETINOPATHY
Diabetic retinopathy is a complication of diabetes that affects the small blood vessels in the retina. It is the leading cause of blindness in working age adults. Strict control of blood sugar and blood pressure can help prevent and slow the progression of diabetic retinopathy. Annual eye exams are important for early detection and treatment if needed to prevent vision loss. As diabetic retinopathy progresses, it is classified into mild, moderate, and severe non-proliferative stages and proliferative stage. Treatments include laser therapy and anti-VEGF injections to prevent further vision loss.
Gos 31 Presentation 1by Dr. Anand Sudhalkar, Baroda
This document summarizes diabetic retinopathy, its presentation and classification. It discusses how prolonged hyperglycemia can lead to end-stage renal disease and retinopathy. It also classifies the stages of retinopathy from mild to proliferative and discusses clinically significant macular edema. Treatment options are outlined depending on the stage of retinopathy and presence of macular edema. Risk factors that can modify the clinical presentation are also mentioned.
Lecture 3: Diabetic Retinopathy
This document provides information about diabetes and diabetic retinopathy for medical students. It outlines learning objectives related to understanding diabetes demographics, diagnosis, complications, and treatments. Key points include that diabetes affects over 29 million Americans and has significant medical costs. Diabetic retinopathy is a leading cause of blindness and its progression can be slowed by controlling blood sugar and blood pressure. The document also defines the stages of diabetic retinopathy and diabetic macular edema.
Diabetic retinopathy
This document discusses diabetic retinopathy (DR), a common complication of diabetes that affects the retina. DR develops over time due to chronic hyperglycemia and causes progressive dysfunction of the retinal blood vessels. The document covers the prevalence of DR, risk factors, classification systems used to stage DR severity, pathophysiology, clinical signs, investigations, prevention strategies, and management options. DR can progress from non-proliferative to proliferative stages and is a leading cause of blindness if left untreated.
New diabetic retinopathy
- Diabetic retinopathy is a leading cause of blindness in people aged 20-74 and affects individuals in their most productive years. The risk and severity of retinopathy increases with longer duration of diabetes and poorer blood glucose control.
- The disease involves microvascular changes including microaneurysms, hemorrhages, hard exudates, and new abnormal blood vessel growth. Without treatment, this can lead to vision loss from macular edema, retinal detachment, or vitreous hemorrhage.
- Treatment involves managing blood sugar and blood pressure, as well as laser photocoagulation surgery or intravitreal injections to prevent vision loss from proliferative retinopathy or macular edema.
Recommended
Diabetic retinopathy group 7 period 2 #
Diabetic retinopathy is damage to the retina caused by long-term diabetes. It affects people with type 1 and type 2 diabetes, especially Hispanics and African Americans over 30 years old. Symptoms include blurred vision and potential complications like cataracts or retinal detachment. The disease infects blood vessels in the eyes, blocking them and causing bleeding and fluid buildup in the retina. Treatment focuses on controlling blood sugar and blood pressure as well as laser treatments and surgery to repair damage.
Presentation p2 good_one[1]
Diabetic retinopathy is a complication of diabetes that affects the eyes. It damages the blood vessels in the retina and can lead to vision loss over time if not treated. People with type 1 or type 2 diabetes, especially those who have had the disease for a long time, are at higher risk. Symptoms may include blurred vision, spots in vision, and eye pain. Treatment focuses on controlling blood sugar and blood pressure as well as laser treatments or surgery in severe cases to prevent further vision loss.
Advances in retina and nutrition in amd
This document discusses advances in treating age-related macular degeneration (AMD) through retina research and nutrition. It defines the two types of AMD - dry and wet - and explains their symptoms and stages. Treatment for dry AMD focuses on antioxidant and zinc supplementation based on the AREDS studies. Wet AMD is treated using anti-VEGF injections into the eye. The role of diet, genetics, and modifiable risk factors like smoking are also discussed. Case studies demonstrate treatment outcomes for patients receiving injections for wet AMD.
DIABETIC RETINOPATHY
Diabetic retinopathy is a complication of diabetes that affects the small blood vessels in the retina. It is the leading cause of blindness in working age adults. Strict control of blood sugar and blood pressure can help prevent and slow the progression of diabetic retinopathy. Annual eye exams are important for early detection and treatment if needed to prevent vision loss. As diabetic retinopathy progresses, it is classified into mild, moderate, and severe non-proliferative stages and proliferative stage. Treatments include laser therapy and anti-VEGF injections to prevent further vision loss.
Gos 31 Presentation 1by Dr. Anand Sudhalkar, Baroda
This document summarizes diabetic retinopathy, its presentation and classification. It discusses how prolonged hyperglycemia can lead to end-stage renal disease and retinopathy. It also classifies the stages of retinopathy from mild to proliferative and discusses clinically significant macular edema. Treatment options are outlined depending on the stage of retinopathy and presence of macular edema. Risk factors that can modify the clinical presentation are also mentioned.
Lecture 3: Diabetic Retinopathy
This document provides information about diabetes and diabetic retinopathy for medical students. It outlines learning objectives related to understanding diabetes demographics, diagnosis, complications, and treatments. Key points include that diabetes affects over 29 million Americans and has significant medical costs. Diabetic retinopathy is a leading cause of blindness and its progression can be slowed by controlling blood sugar and blood pressure. The document also defines the stages of diabetic retinopathy and diabetic macular edema.
Diabetic retinopathy
This document discusses diabetic retinopathy (DR), a common complication of diabetes that affects the retina. DR develops over time due to chronic hyperglycemia and causes progressive dysfunction of the retinal blood vessels. The document covers the prevalence of DR, risk factors, classification systems used to stage DR severity, pathophysiology, clinical signs, investigations, prevention strategies, and management options. DR can progress from non-proliferative to proliferative stages and is a leading cause of blindness if left untreated.
New diabetic retinopathy
- Diabetic retinopathy is a leading cause of blindness in people aged 20-74 and affects individuals in their most productive years. The risk and severity of retinopathy increases with longer duration of diabetes and poorer blood glucose control.
- The disease involves microvascular changes including microaneurysms, hemorrhages, hard exudates, and new abnormal blood vessel growth. Without treatment, this can lead to vision loss from macular edema, retinal detachment, or vitreous hemorrhage.
- Treatment involves managing blood sugar and blood pressure, as well as laser photocoagulation surgery or intravitreal injections to prevent vision loss from proliferative retinopathy or macular edema.
Non proliferative diabetic retinopathy by phaneendra akana
Non-proliferative diabetic retinopathy (NPDR) is a complication of diabetes that causes progressive damage to the retinal blood vessels from high blood sugar levels. It has early stages where there are no symptoms, followed by blurred vision if untreated. Risk factors include the duration of diabetes and poor blood sugar control. As NPDR progresses, it can be classified from mild to severe based on findings like microaneurysms, hemorrhages, cotton-wool spots, and venous changes. Laser treatment may be used if the disease threatens vision. Maintaining good blood sugar control through diet, medication and regular eye exams can help prevent or delay vision loss from diabetic retinopathy.
An Overview of Diabetic Eye Disease
This document provides an overview of diabetic eye disease written by Dr. Anthony Roberts, an eye physician who has performed over 55,000 refractive procedures. It states that diabetes can affect the eyes and cause issues like cataracts, glaucoma, and diabetic retinopathy. Specifically, it notes that cataracts may develop in younger diabetics, glaucoma increases eye pressure and risks nerve damage, and diabetic retinopathy damages retinal blood vessels and is a leading cause of blindness but can be treated.
Can diabetes make me blind AJAY DUDANI
This document discusses how diabetes can potentially cause blindness through diabetic retinopathy and diabetic macular edema. It notes that diabetic retinopathy is one of the most common causes of vision loss in people with diabetes, affecting over 35% of patients. Left untreated, diabetic retinopathy and diabetic macular edema can lead to vision impairment and even blindness. The document provides an overview of diabetic eye diseases, their symptoms, risk factors, and treatment options to help manage and prevent vision loss.
Diabetic disease[1]
Diabetic retinopathy is 25 times more likely to cause blindness in diabetics compared to non-diabetics. The risk increases with longer duration of diabetes, with 50% of patients having retinopathy after 10 years of diabetes diagnosed before age 30 and 90% after 30 years. Microvascular changes in the retina like leakage, hemorrhages, and occlusions can lead to proliferative diabetic retinopathy, characterized by the growth of abnormal blood vessels which can bleed or cause retinal detachment if left untreated. Early annual eye exams and prompt laser treatment when abnormalities are detected can help stabilize the condition and prevent vision loss.
Diabetic retinopathy
Diabetic retinopathy is a complication of diabetes, caused by high blood sugar levels damaging the back of the eye (retina). It can cause blindness if left undiagnosed and untreated. However, it usually takes several years for diabetic retinopathy to reach a stage where it could threaten your sight.
The retina is the light-sensitive layer of cells at the back of the eye that converts light into electrical signals. The signals are sent to the brain which turns them into the images you see.
The retina needs a constant supply of blood, which it receives through a network of tiny blood vessels. Over time, a persistently high blood sugar level can damage these blood vessels in 3 main stages:
background retinopathy – tiny bulges develop in the blood vessels, which may bleed slightly but don't usually affect your vision
pre-proliferative retinopathy – more severe and widespread changes affect the blood vessels, including more significant bleeding into the eye
proliferative retinopathy – scar tissue and new blood vessels, which are weak and bleed easily, develop on the retina, this can result in some loss of vision
Diabetic Retinopathy
Diabetic retinopathy is damage to the retina caused due to complications arising from diabetes. This may eventually lead to blindness. Diabetic retinopathy affects those with high blood sugar over a prolonged period of time. Too much blood sugar can destroy the blood vessels located at the back of the eye, preventing the retina from receiving the much needed nutrients to maintain vision.
In some with prolonged diabetic retinopathy, the blood vessels may swell and leak fluid; while in others abnormal new blood vessels may grow on the surface of the retina causing the light-sensitive tissue to gradually lose vision. Contrary to belief, diabetic retinopathy generally affects both the eyes.
Diabetic Retinopathy Market
Diabetic Retinopathy Market focuses on the global Diabetic Retinopathy status, future forecast, growth opportunity, key market and key players
Diabetes melitis & eye part 1 presentation at www.eyenirvaan.com
This document provides an overview of diabetes mellitus and its effects on the eye. It discusses how diabetes impacts various parts of the eye including the optics, lids, conjunctiva, cornea, iris, lens, accommodation, intraocular pressure, vitreous, retina, optic disc and glaucoma. Specific retinal conditions caused by diabetes like diabetic retinopathy and maculopathy are explained in detail. Treatment options for diabetic macular edema like laser photocoagulation and its focal versus grid approaches are also summarized.
Preventing Vision Loss in Diabetic Retinopathy
This document discusses diabetic retinopathy and methods for preventing vision loss. It describes the stages of diabetic retinopathy from background retinopathy to proliferative retinopathy. It emphasizes that glycemic control through strict management of blood sugar levels is the most effective treatment for preventing and reducing the risk of diabetic retinopathy. Later stages may require laser therapy or angiogenesis inhibitors. Maintaining optimal blood pressure and cholesterol levels also helps prevent vision loss from diabetic retinopathy.
Diabetic retinopathy
A complete source of information intended for ophthalmologists. Includes everything from risk factors to pathophysiology to management.
Messaih of macula FOR DME
1) Ozurdex (dexamethasone intravitreal implant) is effective for treating recalcitrant or non-responsive cases of diabetic macular edema (DME) and retinal vein occlusion (RVO).
2) Ensuring patient compliance with regular treatment is a major challenge in managing DME, and Ozurdex's long duration of action can help control disease progression through improved compliance.
3) Case reports demonstrate that Ozurdex can improve vision in DME and RVO patients who were previously non-responsive or partial responders to anti-VEGF therapies like ranibizumab and aflibercept.
Diabetic Eye Disease
This document provides an overview of diabetic eye disease (diabetic retinopathy). It discusses the prevalence of diabetic retinopathy, symptoms, diagnostic techniques and signs. It describes the pathophysiology of diabetes mellitus and how it relates to damage in the retina. Management of diabetic eye disease and associated conditions are also mentioned.
Diabetic retinopathy.ppt
This document discusses diabetic retinopathy, which is the progressive dysfunction of the retinal blood vessels caused by chronic hyperglycemia. It defines the condition and stages of diabetic retinopathy, from mild non-proliferative to severe proliferative retinopathy. Risk factors include high blood sugar, hypertension, and hyperlipidemia. The document also covers diagnosing, treating, and preventing diabetic retinopathy through strict glycemic control and annual eye exams.
Diabetic Retinopathy by themedicalstuff.com
This document discusses diabetic retinopathy (DR), a complication of diabetes mellitus (DM) characterized by sustained hyperglycemia. Risk factors for DR include duration of DM, poor metabolic control, hypertension, and nephropathy. DR progresses through stages from background DR to proliferative DR. Pathogenesis involves microvascular occlusion and leakage leading to retinal ischemia, neovascularization, and exudation. Late stage complications are diabetic maculopathy and advanced DR with vision-threatening conditions like vitreous hemorrhage.
Diabetic Retinopathy
The document discusses diabetic retinopathy, including its definition, signs and symptoms, causes, risk factors, stages, treatments including laser photocoagulation and intravitreal injections, and importance of glycemic and blood pressure control. It emphasizes the need for regular eye exams in people with diabetes to screen for and treat diabetic eye diseases early.
Retina 1 anatomy and diabetic retinopathy d r.k.n.jha-26.05.16
This document discusses diabetic retinopathy, including its pathogenesis, types, clinical features, diagnosis, and treatment. Diabetic retinopathy is a microangiopathy caused by hyperglycemia that can lead to blindness. It progresses from non-proliferative to proliferative stages and is diagnosed through retinal examination. Treatment involves laser photocoagulation or intravitreal injections to prevent vision loss from macular edema or retinal detachment. Close monitoring and control of blood sugar and other risk factors can help prevent blindness from this common complication of diabetes.
DIABETES MELLITUS AND DIABETIC EYE DISEASE
1) Diabetes mellitus is a metabolic disorder characterized by high blood glucose levels resulting from either the body not producing enough insulin or cells ignoring the insulin.
2) There are two main types of diabetes - type 1 where the body does not produce insulin and always requires insulin treatment, and type 2 where cells ignore insulin and may be managed with diet, exercise or oral medication initially but may later require insulin.
3) Uncontrolled diabetes can lead to serious complications affecting the eyes (such as retinopathy and macular edema), kidneys, nerves, heart, and blood vessels. Intensive control and treatment can help prevent or delay these complications.
Biomarkers of diabetic retinopathy
This document presents information on diabetic retinopathy including its causes, risk factors, stages, diagnosis, and treatment. It begins with an introduction by Sonali Diwate and objectives of the presentation. It then outlines the topics to be discussed and provides details on the types and pathogenesis of diabetic retinopathy. The stages of diabetic retinopathy from mild nonproliferative to proliferative are explained. Risk factors, diagnostic tests, management approaches like laser therapy and anti-VEGF injections, potential biomarkers and conclusions are summarized. The document aims to raise awareness of diabetic retinopathy as a public health problem and discuss treatments and management of the disease.
Diabetic ophthalmopathy
This document discusses diabetic ophthalmopathy, a common sight-threatening complication of diabetes. It begins by stating that diabetes affects about 3% of the global population. Next, it describes the various extra-retinal effects diabetes can have on the eye, including cataracts, glaucoma, retinal vascular diseases, and infections. A major section then focuses on diabetic retinopathy, including its pathogenesis, risk factors, various stages from non-proliferative to proliferative, and management through careful monitoring, laser treatment, and in advanced cases, vitreo-retinal surgery. The document aims to outline the ocular effects of diabetes and treatment approaches for associated conditions like diabetic retinopathy.
Dry Eye and Ocular surface diseases in diabetes mellitus
RELATION OF DIABETES WITH DRY EYE AND OTHER OCULAR SURFACE DISEASES, MADE FOR THE PURPOSE PROTOCOL PRESENTATION. MADE BY DR DHWANIT KHETWANI OPHTHALMOLOGY RESIDENT
DR from physicians perspective.pptx
Diabetic retinopathy is a complication of diabetes that affects the eyes. It is caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). Over time, diabetes can damage these small blood vessels and cause them to leak blood and other fluids into the retina. This can lead to blurred or decreased vision. The document discusses the causes, risk factors, signs, symptoms, stages, treatments, and importance of screening for diabetic retinopathy. Regular eye exams are emphasized to detect diabetic retinopathy early before vision is affected.
DME Management Guidelines
This document provides guidelines for screening, monitoring, classifying severity, and treating diabetic macular edema (DME). It recommends annual screening of diabetic patients aged 15+ for retinopathy and treating any sight-threatening cases found. For DME treatment, it discusses traditional laser photocoagulation as well as newer options like intravitreal corticosteroids and anti-VEGF drugs. Intravitreal injections of anti-VEGF agents are considered first-line therapy for center-involving DME, with laser as an option for non-center cases or if thickening persists after anti-VEGF treatment. Strict control of modifiable risk factors like glycemia, blood pressure, and lipids can also help prevent
More Related Content
What's hot
Non proliferative diabetic retinopathy by phaneendra akana
Non-proliferative diabetic retinopathy (NPDR) is a complication of diabetes that causes progressive damage to the retinal blood vessels from high blood sugar levels. It has early stages where there are no symptoms, followed by blurred vision if untreated. Risk factors include the duration of diabetes and poor blood sugar control. As NPDR progresses, it can be classified from mild to severe based on findings like microaneurysms, hemorrhages, cotton-wool spots, and venous changes. Laser treatment may be used if the disease threatens vision. Maintaining good blood sugar control through diet, medication and regular eye exams can help prevent or delay vision loss from diabetic retinopathy.
An Overview of Diabetic Eye Disease
This document provides an overview of diabetic eye disease written by Dr. Anthony Roberts, an eye physician who has performed over 55,000 refractive procedures. It states that diabetes can affect the eyes and cause issues like cataracts, glaucoma, and diabetic retinopathy. Specifically, it notes that cataracts may develop in younger diabetics, glaucoma increases eye pressure and risks nerve damage, and diabetic retinopathy damages retinal blood vessels and is a leading cause of blindness but can be treated.
Can diabetes make me blind AJAY DUDANI
This document discusses how diabetes can potentially cause blindness through diabetic retinopathy and diabetic macular edema. It notes that diabetic retinopathy is one of the most common causes of vision loss in people with diabetes, affecting over 35% of patients. Left untreated, diabetic retinopathy and diabetic macular edema can lead to vision impairment and even blindness. The document provides an overview of diabetic eye diseases, their symptoms, risk factors, and treatment options to help manage and prevent vision loss.
Diabetic disease[1]
Diabetic retinopathy is 25 times more likely to cause blindness in diabetics compared to non-diabetics. The risk increases with longer duration of diabetes, with 50% of patients having retinopathy after 10 years of diabetes diagnosed before age 30 and 90% after 30 years. Microvascular changes in the retina like leakage, hemorrhages, and occlusions can lead to proliferative diabetic retinopathy, characterized by the growth of abnormal blood vessels which can bleed or cause retinal detachment if left untreated. Early annual eye exams and prompt laser treatment when abnormalities are detected can help stabilize the condition and prevent vision loss.
Diabetic retinopathy
Diabetic retinopathy is a complication of diabetes, caused by high blood sugar levels damaging the back of the eye (retina). It can cause blindness if left undiagnosed and untreated. However, it usually takes several years for diabetic retinopathy to reach a stage where it could threaten your sight.
The retina is the light-sensitive layer of cells at the back of the eye that converts light into electrical signals. The signals are sent to the brain which turns them into the images you see.
The retina needs a constant supply of blood, which it receives through a network of tiny blood vessels. Over time, a persistently high blood sugar level can damage these blood vessels in 3 main stages:
background retinopathy – tiny bulges develop in the blood vessels, which may bleed slightly but don't usually affect your vision
pre-proliferative retinopathy – more severe and widespread changes affect the blood vessels, including more significant bleeding into the eye
proliferative retinopathy – scar tissue and new blood vessels, which are weak and bleed easily, develop on the retina, this can result in some loss of vision
Diabetic Retinopathy
Diabetic retinopathy is damage to the retina caused due to complications arising from diabetes. This may eventually lead to blindness. Diabetic retinopathy affects those with high blood sugar over a prolonged period of time. Too much blood sugar can destroy the blood vessels located at the back of the eye, preventing the retina from receiving the much needed nutrients to maintain vision.
In some with prolonged diabetic retinopathy, the blood vessels may swell and leak fluid; while in others abnormal new blood vessels may grow on the surface of the retina causing the light-sensitive tissue to gradually lose vision. Contrary to belief, diabetic retinopathy generally affects both the eyes.
Diabetic Retinopathy Market
Diabetic Retinopathy Market focuses on the global Diabetic Retinopathy status, future forecast, growth opportunity, key market and key players
Diabetes melitis & eye part 1 presentation at www.eyenirvaan.com
This document provides an overview of diabetes mellitus and its effects on the eye. It discusses how diabetes impacts various parts of the eye including the optics, lids, conjunctiva, cornea, iris, lens, accommodation, intraocular pressure, vitreous, retina, optic disc and glaucoma. Specific retinal conditions caused by diabetes like diabetic retinopathy and maculopathy are explained in detail. Treatment options for diabetic macular edema like laser photocoagulation and its focal versus grid approaches are also summarized.
Preventing Vision Loss in Diabetic Retinopathy
This document discusses diabetic retinopathy and methods for preventing vision loss. It describes the stages of diabetic retinopathy from background retinopathy to proliferative retinopathy. It emphasizes that glycemic control through strict management of blood sugar levels is the most effective treatment for preventing and reducing the risk of diabetic retinopathy. Later stages may require laser therapy or angiogenesis inhibitors. Maintaining optimal blood pressure and cholesterol levels also helps prevent vision loss from diabetic retinopathy.
Diabetic retinopathy
A complete source of information intended for ophthalmologists. Includes everything from risk factors to pathophysiology to management.
Messaih of macula FOR DME
1) Ozurdex (dexamethasone intravitreal implant) is effective for treating recalcitrant or non-responsive cases of diabetic macular edema (DME) and retinal vein occlusion (RVO).
2) Ensuring patient compliance with regular treatment is a major challenge in managing DME, and Ozurdex's long duration of action can help control disease progression through improved compliance.
3) Case reports demonstrate that Ozurdex can improve vision in DME and RVO patients who were previously non-responsive or partial responders to anti-VEGF therapies like ranibizumab and aflibercept.
Diabetic Eye Disease
This document provides an overview of diabetic eye disease (diabetic retinopathy). It discusses the prevalence of diabetic retinopathy, symptoms, diagnostic techniques and signs. It describes the pathophysiology of diabetes mellitus and how it relates to damage in the retina. Management of diabetic eye disease and associated conditions are also mentioned.
Diabetic retinopathy.ppt
This document discusses diabetic retinopathy, which is the progressive dysfunction of the retinal blood vessels caused by chronic hyperglycemia. It defines the condition and stages of diabetic retinopathy, from mild non-proliferative to severe proliferative retinopathy. Risk factors include high blood sugar, hypertension, and hyperlipidemia. The document also covers diagnosing, treating, and preventing diabetic retinopathy through strict glycemic control and annual eye exams.
Diabetic Retinopathy by themedicalstuff.com
This document discusses diabetic retinopathy (DR), a complication of diabetes mellitus (DM) characterized by sustained hyperglycemia. Risk factors for DR include duration of DM, poor metabolic control, hypertension, and nephropathy. DR progresses through stages from background DR to proliferative DR. Pathogenesis involves microvascular occlusion and leakage leading to retinal ischemia, neovascularization, and exudation. Late stage complications are diabetic maculopathy and advanced DR with vision-threatening conditions like vitreous hemorrhage.
Diabetic Retinopathy
The document discusses diabetic retinopathy, including its definition, signs and symptoms, causes, risk factors, stages, treatments including laser photocoagulation and intravitreal injections, and importance of glycemic and blood pressure control. It emphasizes the need for regular eye exams in people with diabetes to screen for and treat diabetic eye diseases early.
Retina 1 anatomy and diabetic retinopathy d r.k.n.jha-26.05.16
This document discusses diabetic retinopathy, including its pathogenesis, types, clinical features, diagnosis, and treatment. Diabetic retinopathy is a microangiopathy caused by hyperglycemia that can lead to blindness. It progresses from non-proliferative to proliferative stages and is diagnosed through retinal examination. Treatment involves laser photocoagulation or intravitreal injections to prevent vision loss from macular edema or retinal detachment. Close monitoring and control of blood sugar and other risk factors can help prevent blindness from this common complication of diabetes.
DIABETES MELLITUS AND DIABETIC EYE DISEASE
1) Diabetes mellitus is a metabolic disorder characterized by high blood glucose levels resulting from either the body not producing enough insulin or cells ignoring the insulin.
2) There are two main types of diabetes - type 1 where the body does not produce insulin and always requires insulin treatment, and type 2 where cells ignore insulin and may be managed with diet, exercise or oral medication initially but may later require insulin.
3) Uncontrolled diabetes can lead to serious complications affecting the eyes (such as retinopathy and macular edema), kidneys, nerves, heart, and blood vessels. Intensive control and treatment can help prevent or delay these complications.
Biomarkers of diabetic retinopathy
This document presents information on diabetic retinopathy including its causes, risk factors, stages, diagnosis, and treatment. It begins with an introduction by Sonali Diwate and objectives of the presentation. It then outlines the topics to be discussed and provides details on the types and pathogenesis of diabetic retinopathy. The stages of diabetic retinopathy from mild nonproliferative to proliferative are explained. Risk factors, diagnostic tests, management approaches like laser therapy and anti-VEGF injections, potential biomarkers and conclusions are summarized. The document aims to raise awareness of diabetic retinopathy as a public health problem and discuss treatments and management of the disease.
Diabetic ophthalmopathy
This document discusses diabetic ophthalmopathy, a common sight-threatening complication of diabetes. It begins by stating that diabetes affects about 3% of the global population. Next, it describes the various extra-retinal effects diabetes can have on the eye, including cataracts, glaucoma, retinal vascular diseases, and infections. A major section then focuses on diabetic retinopathy, including its pathogenesis, risk factors, various stages from non-proliferative to proliferative, and management through careful monitoring, laser treatment, and in advanced cases, vitreo-retinal surgery. The document aims to outline the ocular effects of diabetes and treatment approaches for associated conditions like diabetic retinopathy.
Dry Eye and Ocular surface diseases in diabetes mellitus
RELATION OF DIABETES WITH DRY EYE AND OTHER OCULAR SURFACE DISEASES, MADE FOR THE PURPOSE PROTOCOL PRESENTATION. MADE BY DR DHWANIT KHETWANI OPHTHALMOLOGY RESIDENT
What's hot (20)
Non proliferative diabetic retinopathy by phaneendra akana
Non proliferative diabetic retinopathy by phaneendra akana
Diabetes melitis & eye part 1 presentation at www.eyenirvaan.com
Diabetes melitis & eye part 1 presentation at www.eyenirvaan.com
Retina 1 anatomy and diabetic retinopathy d r.k.n.jha-26.05.16
Retina 1 anatomy and diabetic retinopathy d r.k.n.jha-26.05.16
Dry Eye and Ocular surface diseases in diabetes mellitus
Dry Eye and Ocular surface diseases in diabetes mellitus
Similar to Gene therapy
DR from physicians perspective.pptx
Diabetic retinopathy is a complication of diabetes that affects the eyes. It is caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). Over time, diabetes can damage these small blood vessels and cause them to leak blood and other fluids into the retina. This can lead to blurred or decreased vision. The document discusses the causes, risk factors, signs, symptoms, stages, treatments, and importance of screening for diabetic retinopathy. Regular eye exams are emphasized to detect diabetic retinopathy early before vision is affected.
DME Management Guidelines
This document provides guidelines for screening, monitoring, classifying severity, and treating diabetic macular edema (DME). It recommends annual screening of diabetic patients aged 15+ for retinopathy and treating any sight-threatening cases found. For DME treatment, it discusses traditional laser photocoagulation as well as newer options like intravitreal corticosteroids and anti-VEGF drugs. Intravitreal injections of anti-VEGF agents are considered first-line therapy for center-involving DME, with laser as an option for non-center cases or if thickening persists after anti-VEGF treatment. Strict control of modifiable risk factors like glycemia, blood pressure, and lipids can also help prevent
Diabetes and pills
The document discusses diabetes and its effects on various organs like the eyes, heart, kidneys, nerves etc. It specifically focuses on how diabetes can cause blindness through a condition called diabetic retinopathy. It describes the two types of diabetic retinopathy - non-proliferative and proliferative, and how tight control of blood sugar and treatments like laser therapy can help treat and prevent further vision loss.
DIABETES AND THE EYE
This document discusses the effects of diabetes on the eye. It begins with an introduction to diabetes mellitus and its long-term damaging effects on organs. It then covers the two main types of diabetes and their characteristics. The document discusses the pathogenesis of diabetic retinopathy and how high blood glucose damages blood vessels in the eye. It provides a detailed overview of the stages of diabetic retinopathy from mild non-proliferative to proliferative and potential vision loss outcomes. Management strategies like glucose control, laser therapy, anti-VEGF drugs, and vitrectomy are summarized.
How 3 d oct enhances amd & dme treatment
This document discusses age-related macular degeneration (AMD), its two types (dry and wet), risk factors, epidemiology, and treatments. It defines AMD as a disease that gradually destroys central vision. Dry AMD involves breakdown of light-sensitive cells in the macula, while wet AMD occurs when abnormal blood vessels grow behind the retina. Epidemiology studies find 30% of those over 75 have some form of AMD. Treatments discussed include antioxidants to delay dry AMD progression, and laser therapy, photodynamic therapy, and anti-VEGF injections to treat wet AMD. Several case studies demonstrate treatment outcomes.
DIABETIC RETINOPATHY .pptx
This document discusses diabetic retinopathy, which is a complication of diabetes that affects the eyes. It begins by defining diabetes mellitus and its two main types. It then discusses the various stages of diabetic retinopathy from mild non-proliferative diabetic retinopathy to proliferative diabetic retinopathy. Risk factors like duration of diabetes, blood sugar control, hypertension, and pregnancy are covered. Diagnosis, symptoms, and treatment recommendations are provided. The goal is to educate about this chronic eye condition caused by diabetes and its potential to cause vision loss if not properly managed.
Diabetic Retinopathy_Dr. Bastola.pptx
Diabetic Retinopathy
Dr. Pradeep Bastola, MBBS, MD, MPH
Professor, Department of Ophthalmology,
Chitwan Medical College, Nepal
Diabetic retinopathy
Diabetic retinopathy is caused by damage to the blood vessels in the retina from chronic hyperglycemia. It is the most common retinal vascular disease and a leading cause of vision loss. The risk and severity of diabetic retinopathy increases with longer duration of diabetes, poorer blood glucose control, and presence of other complications like hypertension. The pathogenesis involves microvascular changes like capillary non-perfusion and death of pericytes, as well as increased vascular permeability and neo-vascularization due to elevated levels of vasoactive growth factors. Strict control of blood glucose and other cardiovascular risk factors can help prevent and slow the progression of this vision-threatening condition.
Diabetic retinopathy.pptx on diabetic changes in Retina
Diabetic retinopathy is a leading cause of blindness and its incidence is increasing with the rise of diabetes. Poor glycemic control, longer duration of diabetes, and hypertension are major risk factors. The disease progresses from mild non-proliferative retinopathy to more severe proliferative retinopathy, which is driven by hypoxia-induced VEGF expression that causes abnormal blood vessel growth. Intensive glucose control and blood pressure management can delay the onset and progression of diabetic retinopathy.
Advances in Amd And Oct
This document discusses age-related macular degeneration (AMD) and its treatment. It defines dry and wet AMD and their stages. Dry AMD involves breakdown of light-sensitive cells causing blurred vision. Wet AMD occurs when abnormal blood vessels leak fluid causing rapid vision loss. Treatments for wet AMD include laser, photodynamic therapy, and injections of anti-VEGF drugs like Avastin to block abnormal blood vessel growth. The document presents several case studies demonstrating treatment outcomes and uses imaging to show changes pre- and post-treatment. It also discusses epidemiology and risk factors for AMD and a newly defined condition called age-related choroidal atrophy.
DIABETES AND THE EYE.pptx
1. Diabetic retinopathy is a leading cause of blindness and is caused by damage to the small blood vessels in the retina due to complications from diabetes.
2. There are different clinical stages of diabetic retinopathy ranging from mild non-proliferative diabetic retinopathy to more severe proliferative diabetic retinopathy.
3. Treatment depends on the stage of retinopathy and may include laser photocoagulation surgery, intravitreal injections of anti-VEGF drugs, or vitrectomy surgery in more advanced cases.
Diabetic retinopathy
This document discusses diabetic retinopathy, its causes, stages, treatments, and prevention. It is progressive retinal vessel dysfunction caused by long-term hyperglycemia. Key factors that contribute to its development include hypertension, hyperlipidemia, female sex, pregnancy, smoking, obesity, and poor metabolic control. Stages include non-proliferative and proliferative retinopathy. Treatments include anti-VEGF drugs, laser photocoagulation, vitrectomy, and strict control of blood sugar and blood pressure to prevent its progression.
DIABETES AND THE EYE.pptx
This document discusses diabetic retinopathy, which is a disease of the retina caused by long-term effects of diabetes that can lead to damage of the retina and blindness. It defines diabetic retinopathy and its prevalence, risk factors, pathophysiology, signs and symptoms, classification, proliferative stages, macular edema stages, advanced stages, diagnosis and treatment options including laser photocoagulation, anti-VEGF injections, and vitrectomy surgery. The document provides detailed information on staging and treatment of non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.
DIABETES AND THE EYE.pptx
This document discusses diabetic retinopathy, which is a disease of the retina caused by long-term effects of diabetes that can lead to damage of the retina and blindness. It defines diabetic retinopathy and its prevalence, risk factors, pathophysiology, signs and symptoms, classification, proliferative stages, macular edema stages, advanced stages, diagnosis and treatment options including laser photocoagulation, anti-VEGF injections, and vitrectomy surgery. The document provides detailed information on staging and treatment of non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.
Diabetic retinopathy
This document summarizes diabetic retinopathy. It defines diabetic retinopathy as a chronic progressive sight-threatening disease caused by prolonged hyperglycemia. Key points include:
- Diabetic retinopathy is a leading cause of blindness and its prevalence is increasing globally.
- Risk factors include duration of diabetes, poor glycemic control, pregnancy, hypertension, nephropathy, and smoking.
- It progresses from non-proliferative to proliferative stages and can lead to vision loss through edema, neovascularization, and retinal detachment.
- Treatments like laser photocoagulation and anti-VEGF drugs aim to prevent vision loss by treating proliferative retinopathy and mac
Diabetic retinopathy for GENERAL OPHTHALMOLOGIST
Diabetic retinopathy is damage to the blood vessels of the retina due to diabetes. It can progress to proliferative diabetic retinopathy where new abnormal blood vessels grow on the retina or optic disc which can lead to vision loss. A clinical trial studied whether initial treatment of proliferative diabetic retinopathy with injections of the anti-VEGF drug ranibizumab followed by deferred pan-retinal photocoagulation if needed could provide visual outcomes equal to or better than prompt pan-retinal photocoagulation. At two years, vision was maintained or improved in the ranibizumab group while remaining unchanged in the laser group, suggesting anti-VEGF therapy may delay or reduce the need for laser treatment
Lasers in DIABETIC RETINOPATHY
Diabetic retinopathy is damage to the blood vessels of the retina due to diabetes. A study compared the standard treatment of pan-retinal photocoagulation (PRP) to initial treatment with intravitreal anti-VEGF injections (ranibizumab) to delay or prevent the need for PRP. At 2 years, vision was maintained or improved in the ranibizumab group while vision remained unchanged in the PRP group. The study suggests initial treatment of proliferative diabetic retinopathy with anti-VEGF injections like ranibizumab may be as effective as immediate PRP treatment and could help delay or reduce the need for destructive PRP therapy.
Diabetic and Hypertensive Retinopathy30 3-2011-121109075116-phpapp01 (1)
The document provides information about diabetic retinopathy including:
- It is a microvascular complication of long-standing diabetes mellitus that can cause blindness, and is the most common cause of blindness among working age adults.
- Risk factors include long duration of diabetes, poor blood glucose control, hypertension, and nephropathy.
- It is classified as non-proliferative diabetic retinopathy or proliferative diabetic retinopathy. Signs include microaneurysms, hemorrhages, cotton wool spots, hard exudates, and abnormal blood vessel growth in severe cases.
- Treatment involves tight blood glucose and blood pressure control, as well as laser photocoagulation surgery
Diabetes and hga1c
Diabetes can damage blood vessels and tissues throughout the body by impairing insulin function and increasing glucose levels. This document discusses how diabetes leads to complications in the eyes like retinopathy, and treatments like laser therapy and glucose control that can help prevent vision loss and disease progression. The author is an eye surgeon who specializes in treating diabetic retinopathy and educating patients on diabetes management and eye health.
Diabetic retinopathy
Diabetic retinopathy - introduction,type, risk factors, etdrs classification, airlie classification , diabetic macular edema, dme treatment, diabetic retinopathy screening, diabetic retinopathy studies , diabetic retinopathy treatment, anti-vegf injections
Similar to Gene therapy (20)
Diabetic retinopathy.pptx on diabetic changes in Retina
Diabetic retinopathy.pptx on diabetic changes in Retina
Diabetic and Hypertensive Retinopathy30 3-2011-121109075116-phpapp01 (1)
Diabetic and Hypertensive Retinopathy30 3-2011-121109075116-phpapp01 (1)
Gene therapy
- 1. Gene therapy; A possible cure from diabetic retinopathy Vineeta Sharma Adeno Biosciences, Alameda, CA 94501 Diabetic retinopathy (DR) is the most common diabetic microvascular complication, and is the leading cause of severe vision loss among working-age individuals. Nearly all individuals with type 1 diabetes and more than 60% of those with type 2 have some form of retinopathy after 20 years. Neovascularization caused by severe hypoxia is the hallmark of proliferative diabetic retinopathy (PDR), whereas vascular leakage caused by the breakdown of the blood retinal barrier is involved in the pathogenesis of diabetic macular edema (DME). Intravitreal injections of anti-VEGF or steroidal drugs are being used for the treatment of advanced DR, ME and vitreal hemorrhage. However, reinjections are commonly needed, causing substantial adverse effects such as infection and inflammation. Gene therapy offers long-term expression of the transgene thus minimizing multiple and frequent injection requirement. Anti-VEGF agents have continued as the mainstay of treatment to prevent neovascularization and vascular permeability in DR patients, however, there is a distinct subgroup of patients, which do not respond adequately to anti-VEGF suggesting that other factors may play a role. Recent studies suggest that angiopoietins modulate the angiogenesis and pathological neovascularization with or without VEGF. Hence, we have developed an adeno- associated virus (AAV) based gene transfer system to deliver angiopoietins 1, 2 and 4 into a rat model of DR to study their therapeutic potential. Given that angiopoietins are upregulated under hyperglycemic, hypoxic and inflammatory conditions, we believe that angiopoietin therapy can prevent vision loss and blindness in patients who remain unresponsive to anti-VEGF treatment and will help minimize significant vision loss and blindness.